dc.contributor.authorWilder-Smith, Annelies
dc.contributor.authorMassad, Eduardo
dc.identifier.citationWilder-Smith, A., & Massad, E. (2016). Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Review of Vaccines, 15(4), 437-441.en_US
dc.description.abstractCYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baseline seropositivity, efficacy against hospitalizations and efficacy against severe disease. Because of the higher efficacy and the absence of a safety signal, the age group with the best benefit of the use of CYD-TDV is individuals aged 9 and above - the age group for which licensure is now being sought.en_US
dc.format.extent11 p.en_US
dc.relation.ispartofseriesExpert Review of Vaccinesen_US
dc.rights© 2016 Taylor & Francis. This is the author created version of a work that has been peer reviewed and accepted for publication by Expert Review of Vaccines, Taylor & Francis. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1586/14760584.2016.1143366].en_US
dc.subjectAge indicationen_US
dc.titleAge specific differences in efficacy and safety for the CYD-tetravalent dengue vaccineen_US
dc.typeJournal Article
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)
dc.description.versionAccepted versionen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record